Pembrolizumab in Early Triple-Negative Breast Cancer. Reply

N Engl J Med. 2022 May 5;386(18):1771-1772. doi: 10.1056/NEJMc2203316.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Breast Neoplasms*
  • Female
  • Humans
  • Neoadjuvant Therapy
  • Progression-Free Survival
  • Triple Negative Breast Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab